Cosmos Health Signs Distribution Agreement With ProMed Trading for Its Sky Premium Life Food Supplements in Qatar
Cosmos Health Signs Distribution Agreement With ProMed Trading for Its Sky Premium Life Food Supplements in Qatar
CHICAGO, IL / ACCESSWIRE / July 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has signed a distribution agreement (the "Agreement") with ProMed Trading Company ("ProMed") for its Sky Premium Life food supplement products in Qatar.
2024年7月25日 / Cosmos Health Inc.(“ Cosmos Health”或“公司”)(NASDAQ:COSM)是一家多元化、垂直整合的全球醫療保健集團,從事創新研發,擁有專有藥品和營養保健品牌,生產和分銷保健產品並運營遠程醫療平台。今天宣佈,該公司與ProMed Trading Company(“ProMed”)簽訂分銷協議(“協議”),推廣Sky Premium Life食品補充劑產品在卡塔爾。
ProMed, based in Doha, is a leading healthcare company in Qatar offering a diverse range of medical supplies and equipment, including medical and analytical devices, research and scientific instruments, beauty and health products, disposable and hospital consumables, general medical equipment, infection control products, and dental items.
總部位於多哈的ProMed是卡塔爾的領先醫療保健公司,提供各種醫療用品和設備,包括醫療和分析設備,研究和科學器械,美容和保健產品,一次性和醫院消耗品,一般醫療設備,傳染病控制產品和牙科物品等。
As part of the Agreement, ProMed will handle all key functions, including regulatory compliance, product registration, distribution, promotion, marketing, logistics, and the sale of Sky Premium Life products in pharmacies and shops across Qatar.
作爲協議的一部分,ProMed將處理所有關鍵職能,包括法規合規性,產品註冊,分銷,促銷,營銷,物流以及在卡塔爾各地的藥房和商店銷售Sky Premium Life產品。
According to Business Market Insights, the Middle East and Southeast Asia dietary supplements market, valued at $17.04 billion in 2023, is projected to reach $30.72 billion by 2031, with a CAGR of 7.6%. This growth is driven by rising health awareness, the availability of various supplement formats in retail stores, and increasing disposable income.
根據Business Market Insights的數據,中東和東南亞膳食補充劑市場在2023年價值爲170.4億美元,預計到2031年將達到307.2億美元,年複合增長率爲7.6%。這種增長得益於人們健康意識的提高,各種不同類型的補充劑在零售店的可得性以及可支配收入的增加。
Greg Siokas, CEO of Cosmos Health, stated: "We are delighted to announce our distribution agreement with ProMed, enabling us to dynamically launch Sky Premium Life in the growing market of Qatar. This important partnership is another testament to the high-quality nature of our products and the strong global demand for our brand, following our recent momentum with distribution agreements in the UAE and Eastern Europe."
Cosmos Health的CEO Greg Siokas表示:“我們很高興宣佈與ProMed的分銷協議,使我們能夠在不斷增長的卡塔爾市場上動態推出Sky Premium Life。這一重要合作伙伴關係再次證明了我們產品的高質量性質和我們品牌的全球強勢需求,繼我們最近在阿聯酋和東歐簽署分銷協議後。
About Cosmos Health Inc.
Cosmos Health Inc.(納斯達克:COSM)成立於2009年,總部位於內華達州,是一家全球健康醫療集團公司。公司擁有一系列專有藥品和保健品牌,包括Sky Premium Life,Mediterranation,bio-bebe和C-Sept。公司的子公司Cana Laboratories S.A.獲得歐洲GMP許可和歐洲藥品管理局認證,生產醫藥品、食品補充劑、化妝品、生物滅菌劑和醫療設備等產品,並經營歐盟內的銷售。此外,Cosmos Health還通過希臘和英國的子公司向零售藥店和批發經銷商銷售廣泛的藥品和非處方藥品,包括品牌仿製藥和OTC藥品。此外,該公司還與人工智能藥物再利用技術合作,專注於研發針對肥胖症、糖尿病和癌症等主要健康障礙的研發合作,並專注於研發新的專利營養保健品、特殊植物提取物、專有複合仿製藥和創新非處方藥品。Cosmos Health還通過收購總部位於德克薩斯州的ZipDoctor,Inc進入了遠程醫療領域。公司正在全球範圍內擴張,並在希臘的塞薩洛尼基和雅典、英國的哈洛等地設有辦事處和配送中心。 更多信息請訪問公司網站:,以及LinkedIn和X。
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at , , , , as well as LinkedIn and X.
Cosmos Health Inc.(納斯達克:COSM)於2009年在內華達州成立,是一家多元化、垂直整合的全球保健集團。公司擁有一系列專有的藥品和營養保健品牌,包括Sky Premium Life、Mediterranation、bio-bebe和C-Sept。通過其子公司Cana Laboratories S.A.的許可,該公司在歐洲聯盟範圍內製造藥品、食品補充劑、化妝品、生物殺滅劑和醫療設備,並遵守歐洲藥品管理局(EMA)的認證的歐洲良好生產規範(GMP)。Cosmos Health還通過其在希臘和英國的子公司向零售藥店和批發經銷商分銷包括品牌通用名和場外交易藥物在內的各類藥品和光合生物。此外,公司已經建立了針對肥胖症、糖尿病和癌症等主要健康障礙的研發合作關係,並獲得了人工智能藥物再利用技術增強,專注於新型專利營養保健品、特製根提取物、專有複雜通用名和創新場外交易產品的研發。Cosmos Health還通過收購位於美國德克薩斯州的ZipDoctor,Inc.進入了遠程醫療領域。擁有全球分銷平台,該公司目前正在歐洲、亞洲和北美進行擴張,並在希臘的塞薩洛尼基和雅典,以及英國的哈洛設有辦事處和分銷中心。更多信息可在, , , ,以及LinkedIn和X上獲得。
Forward-Looking Statements
前瞻性聲明
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Cosmos Health Inc.("公司")在本新聞稿中所述的事項中除了包含歷史信息外,還可能包含根據1933年修訂的《證券法》第27A條和1934年修訂的《證券交易法》第21E條的前瞻性陳述。前瞻性聲明涉及未知的風險和不確定性,可能因以下原因之一而對討論的事項產生個別或實質性影響,這在公司的控制範圍之外,包括但不限於公司籌集足夠融資實施其業務計劃的能力,新冠病毒大流行和烏克蘭戰爭對公司業務、運營和經濟的影響以及公司成功開發和商業化自有產品和技術的能力。讀者應該注意不要過度依賴這些前瞻性聲明,因爲實際結果可能與本新聞稿中所述的前瞻性聲明不同。讀者應該注意閱讀證券交易委員會的風險因素,該委員會在其網站上(www.sec.gov)提供了這些信息。本公司不承擔更新或修訂任何前瞻性陳述的義務。
Investor Relations Contact:
投資者關係聯繫人:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
資訊來源:Cosmos Health Inc.
譯文內容由第三人軟體翻譯。